1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exagen Inc.
  6. Financials
    XGN   US30068X1037

EXAGEN INC.

(XGN)
  Report
Delayed Nasdaq  -  05/27 04:00:00 pm EDT
5.130 USD   +1.18%
05/26Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
GL
05/26Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
AQ
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 31916718883,4--
Enterprise Value (EV)1 31916718883,483,483,4
P/E ratio -3,00x-10,00x-6,92x-2,47x-2,91x-4,23x
Yield ------
Capitalization / Revenue 7,90x3,98x3,89x1,56x1,26x0,99x
EV / Revenue 7,90x3,98x3,89x1,56x1,26x0,99x
EV / EBITDA -36,6x-11,4x-8,13x-2,57x-3,12x-4,37x
Price to Book -3,99x2,21x1,56x2,53x3,27x
Nbr of stocks (in thousands) 12 56112 65216 16416 256--
Reference price (USD) 25,413,211,65,135,135,13
Announcement Date 03/25/202003/16/202103/22/2022---
1 USD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 40,442,048,353,466,084,1
EBITDA1 -8,71-14,6-23,1-32,5-26,7-19,1
Operating profit (EBIT)1 -9,30-15,2-24,1-33,5-28,5-20,2
Operating Margin -23,0%-36,2%-49,8%-62,8%-43,1%-24,0%
Pre-Tax Profit (EBT)1 -12,0-16,8-26,7-35,2-30,3-21,0
Net income1 -30,3-16,7-26,9-35,2-30,3-21,0
Net margin -75,0%-39,8%-55,6%-65,9%-45,9%-25,0%
EPS2 -8,46-1,32-1,68-2,08-1,76-1,21
Dividend per Share ------
Announcement Date 03/25/202003/16/202103/22/2022---
1 USD in Million
2 USD
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 12,312,710,412,014,616,4
EBITDA1 -6,26-5,96-9,40-8,93-7,53-6,43
Operating profit (EBIT)1 -6,50-6,25-9,68-9,08-7,78-6,92
Operating Margin -53,1%-49,3%-93,1%-75,5%-53,4%-42,3%
Pre-Tax Profit (EBT)1 -7,18-6,88-10,3-9,65-8,10-7,28
Net income1 -7,18-7,05-10,3-9,65-8,10-7,28
Net margin -58,6%-55,6%-98,8%-80,2%-55,6%-44,5%
EPS2 -0,42-0,42-0,60-0,57-0,48-0,43
Dividend per Share ------
Announcement Date 11/10/202103/22/202205/11/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt ------
Net Cash position ------
Leverage (Debt / EBITDA) ------
Free Cash Flow1 --14,5-22,6-32,6-25,3-18,2
ROE (Net Profit / Equities) --34,2%-42,4%-60,6%-79,1%-53,9%
Shareholders' equity1 -48,763,458,038,339,0
ROA (Net Profit / Asset) --20,0%-26,6%-33,4%-34,5%-20,5%
Assets1 -83,310110587,8103
Book Value Per Share2 -3,315,253,292,031,57
Cash Flow per Share2 --1,11-1,27-1,93-1,52-0,75
Capex1 0,400,462,372,602,102,23
Capex / Sales 1,00%1,08%4,91%4,87%3,18%2,66%
Announcement Date 03/25/202003/16/202103/22/2022---
1 USD in Million
2 USD
Estimates
Key data
Capitalization (USD) 83 393 541
Net sales (USD) 48 299 000
Number of employees 221
Sales / Employee (USD) 218 548
Free-Float 58,9%
Free-Float capitalization (USD) 49 112 783
Avg. Exchange 20 sessions (USD) 305 303
Average Daily Capital Traded 0,37%
EPS & Dividend